StemCell Therapy

A novel method to improve outcomes of surgery to treat epilepsy has now received approval for clinical testing in 13 French hospitals. The approach could provide a better therapeutic perspective against the drug-resistant form of the disease, which constitutes one-third of all cases, and is a development by Human Brain Project scientist Viktor Jirsa and an interdisciplinary team of collaborators.

To help clinicians plan surgery strategies, the scientists created personalized brain models of patients and simulate the spread of abnormal activity during epileptic seizures. The method represents the first example of a personalized brain modeling approach entering the clinic and will now be assessed over four years in a cohort of 356 patients under strict requirements.

How do we currently treat epilepsy?

Epilepsy is a wide-spread neurological disorder that affects around 50 million people worldwide. In many cases, the seizures that mark the disease can be controlled by drugs, but close to a third of all patients are drug-resistant. For them, the only remaining option is surgical removal of the epileptogenic zone, the area from which the seizure activity first emerges and then spreads. During surgery preparation it is critical to localize this area as precisely as possible in the brain, but very challenging with current methods. As a result, surgery outcomes are difficult to predict, with success rates of only around 60%.

This low success rate has largely stayed the same for the last 30 years. We hope our approach can finally improve the odds for patients, says Jirsa. In the Human Brain Project, Jirsa is the Deputy Leader of the research area of Theoretical Neuroscience.

The Human Brain Project and The Virtual Brain

Over the last five years and in large part within the framework of the Human Brain Project, Jirsa and his team worked on an approach that could bring a change. The team has adapted the open network simulator The Virtual Brain towards applications in epilepsy. This work has laid foundations for the project EPINOV, short for Improving EPilepsy surgery management and progNOsis using Virtual brain technology, a consortium coordinated by Fabrice Bartolomei (Hpital de la Timone) that brings together theorists like Jirsa, clinical neuroscientists, in particular from Marseille and Lyon, and the industry partner Dassault Systmes.

After two pilot studies showed promising results for the approach, the EPINOV-consortium has received approval from the French regulatory authority to put their approach to the test in a full-scale multi-centric trial with almost 400 prospective patients.

It represents the worlds first clinical trial ongoing using full brain network modeling, says Jirsa. When the authorization came in, it was like a huge pressure was relieved from me after all this hard work. Then followed last preparations to assure that all steps in the workflow of virtualization and evaluation of the patient brains are in order during the four-year period of the trial.

Bartolomei explains "This type of epilepsy affects millions of patients worldwide. The personalized modeling of epilepsy networks in drug-resistant patients is an innovative and scientifically validated approach, which proposes to enrich the interpretation of neurophysiological and neuroimaging tests, and thus to improve the surgical prognosis of epilepsy in an individualized way".

Jirsa and his close collaborators, Randy McIntosh at Baycrest Center Toronto and Petra Ritter at Charit Berlin, started building The Virtual Brain as an open-source brain network simulation engine from 2010 on, using neuronal population models and structural information from neuroimaging.

In the Human Brain Project environment, the conditions were perfect to go the decisive steps further towards applying it in a clinical context. The science underlying this trial is almost entirely a result of our work in the HBP, Jirsa says.

Simulating epilepsy

First, a personalized brain model is created from data on the individually measured anatomy, structural connectivity and brain dynamics for each patient. Through a series of steps, it is turned into a dynamic model, on which the seizure propagation can be simulated. High-Performance Computing enables the personalization of the brain network models through the application of machine learning.

The resulting brain avatar is customized to the individual patient and allows testing and estimating during surgery preparation. In a small cohort of retrospective surgery patients we were able to demonstrate that the predictions of the patients brain model correlate well with positive surgery outcome, Jirsa explains, and other labs have confirmed our results independently.

In half of the cases, the surgeons will have information from the epilepsy-model in their staff meetings, where therapeutic interventions are planned. It's a blind random design, half of these patients will be operated taking our model predictions into account, the other half will not. After four years, the statistics will show us hopefully to what degree the model predictions changed the surgery practice, results, and outcome, Jirsa says.

Within the EPINOV consortium, the industrial partner Dassault Systmes will develop a virtual brain-based simulation software prototype that could subsequently be provided to clinics worldwide. Headquartered in France, Dassault Systmes is a multinational software company focused on 11 industries including life sciences and the development of patient-centric modeling and simulation experiences.

There is a very big responsibility, Jirsa emphasizes and at the same time its very exciting that we have this chance to improve clinical practice and ultimately patients lives. And if the approach succeeds, it would also be the first modelling-based example of personalized medicine that makes the jump from research to clinical practice so the outcome will certainly be a signal to the field.

Katrin Amunts, Scientific Research Director of the Human Brain Project, highlights the significance of the move into the clinic: This breakthrough by Viktor Jirsa and his colleagues is a fantastic example of a new type of technology-enabled computational neuro-medicine. It is one of our central aims to catalyze developments like this that make concrete contributions in the fight against brain diseases to benefit patients.

Philippe Ryvlin, who leads the Medical Informatics Platform in HBP and the epilepsy surgery section of the European Reference Network EpiCARE emphasizes that this clinical trial, which will be the largest randomized study ever performed in epilepsy surgery, demonstrates that simulation of the human brain, as developed in HBP, has now reached a stage where it can be readily applied to address unmet medical needs.

Virtual Brain Researchers are also continuing their activities on clinical modeling for stroke and Alzheimers in collaboration with experts that the HBP brings together. For Jirsa seeing his work as a theoretical scientist gain this potential impact has been the result of a unique convergence: That we have come to this point was made possible by clinical expertise and our activities on The Virtual Brain and the Human Brain Project all coming together right place, right time, right people."

Reference

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
Simulation-based Method To Target Epilepsy Goes to Clinical Trials - Technology Networks

This entry was posted on November 13, 2019 at 6:52 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |